Yet another study of hydroxychloroquine has found no evidence of benefit from a malaria drug widely promoted as a treatment for coronavirus infection.
Early studies suggested that the malaria and lupus drug might have antiviral and anti-inflammatory effects might help coronavirus patients, triggering a flurry of research, President Trump’s endorsement and emergency FDA authorization.
But hydroxychloroquine did not lower the risk of dying or needing a breathing tube in a comparison that involved nearly 1,400 patients treated at Columbia University in New York, researchers reported Thursday in the New England Journal of Medicine.
Read more of the original article from DailyMail
